Roth Capital Downgrades Gemphire Therapeutics (GEMP) to Neutral Citing Lack of Catalysts
Tweet Send to a Friend
Roth Capital downgraded Gemphire Therapeutics (NASDAQ: GEMP) from Buy to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
